{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:05:06Z","timestamp":1788635106386,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T00:00:00Z","timestamp":1551916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T00:00:00Z","timestamp":1551916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Millenium"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007072","name":"Amgen Inc. | Onyx Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We compared the outcomes of 310 patients with newly diagnosed multiple myeloma with del(17p) detected by FISH to patients with high-risk translocations (HRT) (<jats:italic>n<\/jats:italic>\u2009=\u200979) and standard-risk (SR) cytogenetics (<jats:italic>n<\/jats:italic>\u2009=\u2009541). The median progression-free survival (PFS) following initial therapy for the three groups was 21.1, 22, and 30.1 months, respectively (<jats:italic>P<\/jats:italic>\u2009=\u20090.437- del(17p) vs. HRT); the median overall survival (OS) was 47.3, 79.1, and 109.8 months, respectively, (<jats:italic>P<\/jats:italic>\u2009=\u20090.007- del(17p) vs. HRT). PFS and OS for patients with relative loss of 17p (<jats:italic>n<\/jats:italic>\u2009=\u200921) were comparable to other patients with del(17p). The PFS was similar between the del(17p) and HRT groups when stratified for age, ISS stage or treatment. The OS of del(17p) and HRT groups were similar in presence of advanced age, ISS III stage or if patients did not receive a proteasome-inhibitor containing induction. ISS III stage, high LDH and HRT, but not the percentage of cells with del(17p) predicted shorter OS in patients with del(17p). The median OS for low (ISS I, normal LDH and no HRT), intermediate (neither low nor high-risk) and high-risk (ISS III and either elevated LDH or coexistent HRT) groups among del(17p) patients were 96.2, 45.4, and 22.8 months, respectively, allowing further risk stratification.<\/jats:p>","DOI":"10.1038\/s41408-019-0191-y","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T13:04:35Z","timestamp":1551963875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Natural history of multiple myeloma with de novo del(17p)"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8915-2382","authenticated-orcid":false,"given":"Arjun","family":"Lakshman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utkarsh","family":"Painuly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia T.","family":"Greipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie L.","family":"Fonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam A.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Lisa","family":"Hwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3495","authenticated-orcid":false,"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taxiarchis V.","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Lust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Zeldenrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"key":"191_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 68, 7\u201330 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"191_CR2","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar, S. K. et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111, 2516\u20132520 (2008).","journal-title":"Blood"},{"key":"191_CR3","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar, S. K. et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28, 1122\u20131128 (2014).","journal-title":"Leukemia"},{"key":"191_CR4","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp, P. R. et al. International staging system for multiple myeloma. J. Clin. Oncol. 23, 3412\u20133420 (2005).","journal-title":"J. Clin. Oncol."},{"key":"191_CR5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael, J. R. et al. Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013. Mayo Clin. Proc. 88, 360\u2013376 (2013).","journal-title":"Mayo Clin. Proc."},{"key":"191_CR6","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J. Clin. Oncol. 33, 2863\u20132869 (2015).","journal-title":"J. Clin. Oncol."},{"key":"191_CR7","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1200\/JCO.2000.18.4.804","volume":"18","author":"R Konigsberg","year":"2000","unstructured":"Konigsberg, R. et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J. Clin. Oncol. 18, 804\u2013812 (2000).","journal-title":"J. Clin. Oncol."},{"key":"191_CR8","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","volume":"101","author":"R Fonseca","year":"2003","unstructured":"Fonseca, R. et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101, 4569\u20134575 (2003).","journal-title":"Blood"},{"key":"191_CR9","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","volume":"109","author":"H Avet-Loiseau","year":"2007","unstructured":"Avet-Loiseau, H. et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 109, 3489\u20133495 (2007).","journal-title":"Blood"},{"key":"191_CR10","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Prim. 3, 17046 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"191_CR11","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1200\/JCO.2011.36.5726","volume":"30","author":"H Avet-Loiseau","year":"2012","unstructured":"Avet-Loiseau, H. et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J. Clin. Oncol. 30, 1949\u20131952 (2012).","journal-title":"J. Clin. Oncol."},{"key":"191_CR12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1046\/j.1365-2141.1999.01615.x","volume":"106","author":"H Avet-Loiseau","year":"1999","unstructured":"Avet-Loiseau, H. et al. P53 deletion is not a frequent event in multiple myeloma. Br. J. Haematol. 106, 717\u2013719 (1999).","journal-title":"Br. J. Haematol."},{"key":"191_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1182\/blood-2004-04-1363","volume":"105","author":"H Chang","year":"2005","unstructured":"Chang, H., Qi, C., Yi, Q. L., Reece, D. & Stewart, A. K. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 105, 358\u2013360 (2005).","journal-title":"Blood"},{"issue":"Suppl 1","key":"191_CR14","first-page":"394","volume":"130","author":"N Testoni","year":"2017","unstructured":"Testoni, N. et al. High-risk cytogenetics in newly diagnosed multiple myeloma: prognostic relevance of co-segregations and analysis of the role of double versus single autotransplantation. Blood 130(Suppl 1), 394 (2017).","journal-title":"Blood"},{"key":"191_CR15","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.3324\/haematol.2017.168872","volume":"102","author":"S Thanendrarajan","year":"2017","unstructured":"Thanendrarajan, S. et al. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica 102, e364\u2013e367 (2017).","journal-title":"Haematologica"},{"key":"191_CR16","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1046\/j.1365-2141.2002.03529.x","volume":"117","author":"Z Niklas","year":"2002","unstructured":"Niklas, Z. et al. Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance. Br. J. Haematol. 117, 852\u2013859 (2002).","journal-title":"Br. J. Haematol."},{"key":"191_CR17","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1365-2141.2007.06649.x","volume":"138","author":"H Chang","year":"2007","unstructured":"Chang, H., Yeung, J., Qi, C. & Xu, W. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma. Br. J. Haematol. 138, 324\u2013329 (2007).","journal-title":"Br. J. Haematol."},{"key":"191_CR18","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar, S. et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 119, 2100\u20132105 (2012).","journal-title":"Blood"},{"key":"191_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00277-003-0632-2","volume":"82","author":"MM Ortega","year":"2003","unstructured":"Ortega, M. M. et al. A possible role of the P53 gene deletion as a prognostic factor in multiple myeloma. Ann. Hematol. 82, 405\u2013409 (2003).","journal-title":"Ann. Hematol."},{"key":"191_CR20","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1182\/blood-2007-10-119123","volume":"112","author":"W Xiong","year":"2008","unstructured":"Xiong, W. et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 112, 4235\u20134246 (2008).","journal-title":"Blood"},{"key":"191_CR21","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/sj.leu.2401609","volume":"13","author":"B Schultheis","year":"1999","unstructured":"Schultheis, B. et al. Analysis of p73 and p53 gene deletions in multiple myeloma. Leukemia 13, 2099\u20132103 (1999).","journal-title":"Leukemia"},{"key":"191_CR22","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2008.4","volume":"22","author":"RE Tiedemann","year":"2008","unstructured":"Tiedemann, R. E. et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 22, 1044 (2008).","journal-title":"Leukemia"},{"key":"191_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1365-2141.2004.05199.x","volume":"127","author":"H Chang","year":"2004","unstructured":"Chang, H., Sloan, S., Li, D. & Keith Stewart, A. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br. J. Haematol. 127, 280\u2013284 (2004).","journal-title":"Br. J. Haematol."},{"key":"191_CR24","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V92.3.802","volume":"92","author":"J Drach","year":"1998","unstructured":"Drach, J. et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 92, 802\u2013809 (1998).","journal-title":"Blood"},{"key":"191_CR25","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1182\/blood-2004-04-1363","volume":"105","author":"H Chang","year":"2005","unstructured":"Chang, H., Qi, C., Yi, Q.-L., Reece, D. & Stewart, A. K. p53gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 105, 358\u2013360 (2005).","journal-title":"Blood"},{"key":"191_CR26","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/sj.leu.2404172","volume":"20","author":"WJ Chng","year":"2006","unstructured":"Chng, W. J. et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia 20, 807 (2006).","journal-title":"Leukemia"},{"key":"191_CR27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/leu.2011.204","volume":"26","author":"KD Boyd","year":"2012","unstructured":"Boyd, K. D. et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 26, 349\u2013355 (2012).","journal-title":"Leukemia"},{"key":"191_CR28","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1182\/blood-2014-07-584268","volume":"125","author":"C Pawlyn","year":"2015","unstructured":"Pawlyn, C. et al. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood 125, 831\u2013840 (2015).","journal-title":"Blood"},{"key":"191_CR29","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/blood-2014-07-587964","volume":"125","author":"B Hebraud","year":"2015","unstructured":"Hebraud, B. et al. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. Blood 125, 2095\u20132100 (2015).","journal-title":"Blood"},{"key":"191_CR30","doi-asserted-by":"publisher","first-page":"E473","DOI":"10.1002\/ajh.24533","volume":"91","author":"M Merz","year":"2016","unstructured":"Merz, M. et al. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. Am. J. Hematol. 91, E473\u2013e7 (2016).","journal-title":"Am. J. Hematol."},{"key":"191_CR31","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/leu.2017.179","volume":"32","author":"V Shah","year":"2017","unstructured":"Shah, V. et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia 32, 102 (2017).","journal-title":"Leukemia"},{"key":"191_CR32","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1038\/leu.2014.102","volume":"28","author":"PJ Teoh","year":"2014","unstructured":"Teoh, P. J. et al. p53 haploinsufficiency and functional abnormalities in multiple myeloma. Leukemia 28, 2066\u20132074 (2014).","journal-title":"Leukemia"},{"key":"191_CR33","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.3390\/ijms17122003","volume":"17","author":"AB Herrero","year":"2016","unstructured":"Herrero, A. B., Rojas, E. A., Misiewicz-Krzeminska, I., Krzeminski, P. & Guti\u00e9rrez, N. C. Molecular mechanisms of p53 deregulation in cancer: an overview in multiple myeloma. Int. J. Mol. Sci. 17, 2003 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"191_CR34","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/sj.leu.2404524","volume":"21","author":"WJ Chng","year":"2007","unstructured":"Chng, W. J. et al. Clinical significance of TP53 mutation in myeloma. Leukemia 21, 582\u2013584 (2007).","journal-title":"Leukemia"},{"key":"191_CR35","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","volume":"33","author":"BA Walker","year":"2015","unstructured":"Walker, B. A. et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J. Clin. Oncol. 33, 3911\u20133920 (2015).","journal-title":"J. Clin. Oncol."},{"key":"191_CR36","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3324\/haematol.2010.023697","volume":"95","author":"L Lod\u00e9","year":"2010","unstructured":"Lod\u00e9, L. et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica 95, 1973\u20131976 (2010).","journal-title":"Haematologica"},{"key":"191_CR37","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/gcc.20899","volume":"50","author":"KD Boyd","year":"2011","unstructured":"Boyd, K. D. et al. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes, Chromosomes & Cancer 50, 765\u2013774 (2011).","journal-title":"Genes, Chromosomes & Cancer"},{"key":"191_CR38","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/bjh.13171","volume":"168","author":"KM Kort\u00fcm","year":"2015","unstructured":"Kort\u00fcm, K. M. et al. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3)P) in -17p high risk disease. Br. J. Haematol. 168, 507\u2013510 (2015).","journal-title":"Br. J. Haematol."},{"key":"191_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.76","volume":"7","author":"M Chin","year":"2017","unstructured":"Chin, M. et al. Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival. Blood Cancer J. 7, e610 (2017).","journal-title":"Blood Cancer J."},{"issue":"Suppl 1","key":"191_CR40","first-page":"4331","volume":"130","author":"V Shah","year":"2017","unstructured":"Shah, V. et al. Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients. Blood 130(Suppl 1), 4331 (2017).","journal-title":"Blood"},{"key":"191_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.15","volume":"6","author":"M Binder","year":"2016","unstructured":"Binder, M. et al. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer J. 6, e401 (2016).","journal-title":"Blood Cancer J."},{"key":"191_CR42","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"key":"191_CR43","doi-asserted-by":"crossref","unstructured":"International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol. 121, 749\u2013757 (2003).","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"191_CR44","first-page":"25","volume":"113","author":"PR Greipp","year":"2005","unstructured":"Greipp, P. R. & Kumar, S. Plasma cell labeling index. Methods Mol. Med. 113, 25\u201335 (2005).","journal-title":"Methods Mol. Med."},{"key":"191_CR45","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"191_CR46","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar, S. V. et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117, 4691\u20134695 (2011).","journal-title":"Blood"},{"key":"191_CR47","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","volume":"28","author":"H Avet-Loiseau","year":"2010","unstructured":"Avet-Loiseau, H. et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J. Clin. Oncol. 28, 4630\u20134634 (2010).","journal-title":"J. Clin. Oncol."},{"key":"191_CR48","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld, P. et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J. Clin. Oncol. 30, 2946\u20132955 (2012).","journal-title":"J. Clin. Oncol."},{"key":"191_CR49","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","volume":"119","author":"K Neben","year":"2012","unstructured":"Neben, K. et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 119, 940\u2013948 (2012).","journal-title":"Blood"},{"key":"191_CR50","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/leu.2013.86","volume":"27","author":"SV Rajkumar","year":"2013","unstructured":"Rajkumar, S. V. et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 27, 1738\u20131744 (2013).","journal-title":"Leukemia"},{"key":"191_CR51","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","volume":"31","author":"K Neben","year":"2013","unstructured":"Neben, K. et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J. Clin. Oncol. 31, 4325\u20134332 (2013).","journal-title":"J. Clin. Oncol."},{"key":"191_CR52","doi-asserted-by":"crossref","unstructured":"Lakshman A., et al. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia. 32, 1811\u20131815 (2018).","DOI":"10.1038\/s41375-018-0030-3"},{"key":"191_CR53","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-14-2576","volume":"21","author":"G An","year":"2015","unstructured":"An, G. et al. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. Clin. Cancer Res. 21, 2148\u20132156 (2015).","journal-title":"Clin. Cancer Res."},{"key":"191_CR54","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","volume":"120","author":"AJ Jakubowiak","year":"2012","unstructured":"Jakubowiak, A. J. et al. A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 120, 1801\u20131809 (2012).","journal-title":"Blood"},{"key":"191_CR55","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","volume":"3","author":"NC Munshi","year":"2017","unstructured":"Munshi, N. C. et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 3, 28\u201335 (2017).","journal-title":"JAMA Oncol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0191-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0191-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0191-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T16:11:38Z","timestamp":1671207098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0191-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,7]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["191"],"URL":"https:\/\/doi.org\/10.1038\/s41408-019-0191-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,7]]},"assertion":[{"value":"26 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.D. received research funding from Celgene, Millennium, Pfizer, and Janssen and travel grant from Pfizer. M.A.G. received consultancy from Millenium and honoraria from Celgene, Millenium, Onyx, Novartis, Smith Kline, Prothena, Ionis, and Amgen. M.Q.L. received research funding from Celgene. P.K. received research funding from Takeda, Celgene, and Amgen. S.K.K. received consultancy from Celgene, Millennium, Onyx, Janssen, and BMS and research funding from Celgene, Millennium, Novartis, Onyx AbbVie, Janssen, and BMS. The remaining authors declare no conflict of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"32"}}